Brought to you by 
Hua gets preclinical glucokinase activators from Roche
08 Mar 2019
Executive Summary
Chinese start-up Hua Medicine Ltd. has received exclusive global rights to develop, manufacture, and sell a group of Roche’s preclinical glucokinase activators including RO5305552 for Type II diabetes. Hua also has a license to preclinical and clinical documentation, and back-up candidates. NOTE: RO5305552 is also known as HMS5552, dorzagliatin, and sinogliatin.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Hua gets preclinical glucokinase activators from Roche
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice